雷莫司琼预防腹腔镜胆囊切除术后恶心和呕吐:随机对照试验。

Yoshitaka Fujii, Aki Uemura, Hiroyoshi Tanaka
{"title":"雷莫司琼预防腹腔镜胆囊切除术后恶心和呕吐:随机对照试验。","authors":"Yoshitaka Fujii,&nbsp;Aki Uemura,&nbsp;Hiroyoshi Tanaka","doi":"10.1080/11024150201680002","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the efficacy and safety of ramosetron (a 5-hydroxytryptamine type 3 receptor antagonist) for the prevention of nausea and vomiting after laparoscopic cholecystectomy.</p><p><strong>Design: </strong>Prospective, randomised, double-blind, placebo-controlled study.</p><p><strong>Setting: </strong>University and university-affiliated hospitals, Japan.</p><p><strong>Subjects: </strong>100 patients, 65 women and 35 men, who had laparoscopic cholecystectomy.</p><p><strong>Interventions: </strong>Patients were given either placebo or ramosetron at 3 different doses (0.15 mg, 0.3 mg, 0.6 mg) intravenously at the completion of operation. The general anaesthetic technique and postoperative analgesia were standard.</p><p><strong>Main outcome measures: </strong>Vomiting and safety were assessed for 0 to 24 hours and 24 to 48 hours after anaesthesia.</p><p><strong>Results: </strong>The number of patients who had a complete response (no nausea, no retching, no vomiting) during 0 to 24 hours after anaesthesia was 15/25 with placebo, 17/25 with ramosetron 0.15 mg, 23/25 with ramosetron 0.3 mg, and 23/25 with ramosetron 0.6 mg; The corresponding numbers from 24 to 48 hours were 16, 17, 23, and 23. No serious adverse events were observed in any of the groups.</p><p><strong>Conclusions: </strong>Ramosetron 0.3 mg was the minimum effective dose for preventing postoperative nausea and vomiting during 0 to 48 hours after anaesthesia in patients undergoing laparoscopic cholecystectomy.</p>","PeriodicalId":22411,"journal":{"name":"The European journal of surgery = Acta chirurgica","volume":"168 11","pages":"583-6"},"PeriodicalIF":0.0000,"publicationDate":"2002-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"29","resultStr":"{\"title\":\"Prophylaxis of nausea and vomiting after laparoscopic cholecystectomy with ramosetron: randomised controlled trial.\",\"authors\":\"Yoshitaka Fujii,&nbsp;Aki Uemura,&nbsp;Hiroyoshi Tanaka\",\"doi\":\"10.1080/11024150201680002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To evaluate the efficacy and safety of ramosetron (a 5-hydroxytryptamine type 3 receptor antagonist) for the prevention of nausea and vomiting after laparoscopic cholecystectomy.</p><p><strong>Design: </strong>Prospective, randomised, double-blind, placebo-controlled study.</p><p><strong>Setting: </strong>University and university-affiliated hospitals, Japan.</p><p><strong>Subjects: </strong>100 patients, 65 women and 35 men, who had laparoscopic cholecystectomy.</p><p><strong>Interventions: </strong>Patients were given either placebo or ramosetron at 3 different doses (0.15 mg, 0.3 mg, 0.6 mg) intravenously at the completion of operation. The general anaesthetic technique and postoperative analgesia were standard.</p><p><strong>Main outcome measures: </strong>Vomiting and safety were assessed for 0 to 24 hours and 24 to 48 hours after anaesthesia.</p><p><strong>Results: </strong>The number of patients who had a complete response (no nausea, no retching, no vomiting) during 0 to 24 hours after anaesthesia was 15/25 with placebo, 17/25 with ramosetron 0.15 mg, 23/25 with ramosetron 0.3 mg, and 23/25 with ramosetron 0.6 mg; The corresponding numbers from 24 to 48 hours were 16, 17, 23, and 23. No serious adverse events were observed in any of the groups.</p><p><strong>Conclusions: </strong>Ramosetron 0.3 mg was the minimum effective dose for preventing postoperative nausea and vomiting during 0 to 48 hours after anaesthesia in patients undergoing laparoscopic cholecystectomy.</p>\",\"PeriodicalId\":22411,\"journal\":{\"name\":\"The European journal of surgery = Acta chirurgica\",\"volume\":\"168 11\",\"pages\":\"583-6\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2002-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"29\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The European journal of surgery = Acta chirurgica\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/11024150201680002\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The European journal of surgery = Acta chirurgica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/11024150201680002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 29

摘要

目的:评价雷莫司琼(5-羟色胺3型受体拮抗剂)预防腹腔镜胆囊切除术后恶心呕吐的疗效和安全性。设计:前瞻性、随机、双盲、安慰剂对照研究。地点:日本大学及大学附属医院。对象:行腹腔镜胆囊切除术的100例患者,其中女性65例,男性35例。干预措施:患者在手术结束时静脉给予安慰剂或3种不同剂量的雷莫司琼(0.15 mg, 0.3 mg, 0.6 mg)。全麻技术及术后镇痛均符合标准。主要结局指标:麻醉后0 ~ 24小时和24 ~ 48小时评估呕吐和安全性。结果:麻醉后0 ~ 24小时内完全缓解(无恶心、无干呕、无呕吐)的患者人数为:安慰剂组15/25,雷莫司琼0.15 mg组17/25,雷莫司琼0.3 mg组23/25,雷莫司琼0.6 mg组23/25;24 ~ 48小时对应的数字分别为16、17、23、23。两组均未见严重不良事件发生。结论:腹腔镜胆囊切除术患者麻醉后0 ~ 48小时内预防术后恶心呕吐的最小有效剂量为雷莫司琼0.3 mg。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Prophylaxis of nausea and vomiting after laparoscopic cholecystectomy with ramosetron: randomised controlled trial.

Objective: To evaluate the efficacy and safety of ramosetron (a 5-hydroxytryptamine type 3 receptor antagonist) for the prevention of nausea and vomiting after laparoscopic cholecystectomy.

Design: Prospective, randomised, double-blind, placebo-controlled study.

Setting: University and university-affiliated hospitals, Japan.

Subjects: 100 patients, 65 women and 35 men, who had laparoscopic cholecystectomy.

Interventions: Patients were given either placebo or ramosetron at 3 different doses (0.15 mg, 0.3 mg, 0.6 mg) intravenously at the completion of operation. The general anaesthetic technique and postoperative analgesia were standard.

Main outcome measures: Vomiting and safety were assessed for 0 to 24 hours and 24 to 48 hours after anaesthesia.

Results: The number of patients who had a complete response (no nausea, no retching, no vomiting) during 0 to 24 hours after anaesthesia was 15/25 with placebo, 17/25 with ramosetron 0.15 mg, 23/25 with ramosetron 0.3 mg, and 23/25 with ramosetron 0.6 mg; The corresponding numbers from 24 to 48 hours were 16, 17, 23, and 23. No serious adverse events were observed in any of the groups.

Conclusions: Ramosetron 0.3 mg was the minimum effective dose for preventing postoperative nausea and vomiting during 0 to 48 hours after anaesthesia in patients undergoing laparoscopic cholecystectomy.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信